Figure 1.

Patient enrollment flow chart. Two hundred and two patients were screened for enrollment; screening of 55 patients failed, resulting in enrollment of 147 patients (72 in the rosuvastatin arm, and 75 in the placebo arm). ^ahigh-sensitivity C-reactive protein level of <2 mg/L; ^bCD8⁺ T-cell expression of CD38 and HLA-DR antigens <19%; ^cthe patient was found to have very high coronary calcium score by computed tomography on the same day as screening, and it was deemed unethical for the patient to be potentially randomly assigned to the placebo group. Abbreviations: CrCl, creatinine clearance; LDL, low-density lipoprotein; LFT, liver function test; TG, triglycerides.